The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Vancomycin Plus Piperacillin-Tazobactam and Acute Kidney Injury in Adults: A Systematic Review and Meta-Analysis
Open accessAbstract
Objectives: The objective of this systematic review and meta-analysis was to assess acute kidney injury with combination therapy of vancomycin plus piperacillin-tazobactam, in general, adult patients and in critically ill adults. Rates of acute kidney injury, time to acute kidney injury, and odds of acute kidney injury were compared with vancomycin monotherapy, vancomycin plus cefepime or carbapenem, or piperacillin-tazobactam monotherapy. Data Sources: Studies were identified by searching Pubmed, Embase, Web of Science, and Cochrane from inception to April 2017. Abstracts from selected conference proceedings were manually searched. Study Selection: Articles not in English, pediatric studies, and case reports were excluded. Data Extraction: Two authors independently extracted data on study methods, rates of acute kidney injury, and time to acute kidney injury. Effect estimates and 95% CIs were calculated using the random effects model in RevMan 5.3. Data Synthesis: Literature search identified 15 published studies and 17 conference abstracts with at least 24,799 patients. The overall occurrence rate of acute kidney injury was 16.7%, with 22.2% for vancomycin plus piperacillin-tazobactam and 12.9% for comparators. This yielded an overall number needed to harm of 11. Time to acute kidney injury was faster for vancomycin plus piperacillin-tazobactam than vancomycin plus cefepime or carbapenem, but not significantly (mean difference, –1.30; 95% CI, –3.00 to 0.41 d). The odds of acute kidney injury with vancomycin plus piperacillin-tazobactam were increased versus vancomycin monotherapy (odds ratio, 3.40; 95% CI, 2.57–4.50), versus vancomycin plus cefepime or carbapenem (odds ratio, 2.68; 95% CI, 1.83–3.91), and versus piperacillin-tazobactam monotherapy (odds ratio, 2.70; 95% CI, 1.97–3.69). In a small subanalysis of 968 critically ill patients, the odds of acute kidney injury were increased versus vancomycin monotherapy (odds ratio, 9.62; 95% CI, 4.48–20.68), but not significantly different for vancomycin plus cefepime or carbapenem (odds ratio, 1.43; 95% CI, 0.83–2.47) or piperacillin-tazobactam monotherapy (odds ratio, 1.35; 95% CI, 0.86–2.11). Conclusions: The combination of vancomycin plus piperacillin-tazobactam increased the odds of acute kidney injury over vancomycin monotherapy, vancomycin plus cefepime or carbapenem, and piperacillin-tazobactam monotherapy. Limited data in critically ill patients suggest the odds of acute kidney injury are increased versus vancomycin monotherapy, and mitigated versus the other comparators. Further research in the critically ill population is needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wan, X., Wang, W., Liu, J., & Tong, T. (2014) · BMC Medical Research Methodology · doi:10.1186/1471-2288-14-135 · Cited by 11,735
Rybak, M., Lomaestro, B., Rotschafer, J. C., Moellering, R., Craig, W., Billeter, M., Dalovisio, J. R., & Levine, D. P. (2009) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp080434 · Cited by 1,795
Cited by
Peerapornratana, S., Manrique-Caballero, C. L., Gómez, H., & Kellum, J. A. (2019) · Kidney International · doi:10.1016/j.kint.2019.05.026 · Cited by 1,471
Tong, S. Y. C., Lye, D. C., Yahav, D., Sud, A., Robinson, J. O., Nelson, J., Archuleta, S., Roberts, M. A., Cass, A., Paterson, D. L., et al. (2020) · JAMA · doi:10.1001/jama.2020.0103 · Cited by 279
Pharmacology behind Common Drug Nephrotoxicities
Perazella, M. A. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00150118 · Cited by 270
Broad-spectrum antibiotic use and poor outcomes in community-onset pneumonia: A cohort study.
Webb, B. J., Sorensen, J., Jephson, A., Mecham, I., & Dean, N. C. (2019) · European Respiratory Journal · doi:10.1183/13993003.00057-2019 · Cited by 164
Rapid Detection of Methicillin-Resistant Staphylococcus aureus in BAL
Paonessa, J. R., Shah, R. D., Pickens, C. I., Lizza, B. D., Donnelly, H. K., Malczynski, M., Qi, C., & Wunderink, R. G. (2019) · Chest · doi:10.1016/j.chest.2019.02.007 · Cited by 66
Metadata
- Authors
- Luther, M. K., Timbrook, T. T., Caffrey, A. R., Dosa, D., Lodise, T. P., & LaPlante, K. L.
- Venue
- Critical Care Medicine
- Published
- 2018-01
- Volume
- 46
- Issue
- 1
- Pages
- 12-20
- ISSN
- 0090-3493 (ISSN-L)
- OpenAlex
- W2765826512
- Cited by
- 235
- References
- 2
- FWCI
- 4.48
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Vancomycin Plus Piperacillin-Tazobactam and Acute Kidney Injury in Adults: A Systematic Review and Meta-Analysis. https://app.cochat.ai/papers/10.1097/ccm.0000000000002769
- The paper
- Luther, M. K., Timbrook, T. T., Caffrey, A. R., Dosa, D., Lodise, T. P., & LaPlante, K. L. (2018). Vancomycin Plus Piperacillin-Tazobactam and Acute Kidney Injury in Adults: A Systematic Review and Meta-Analysis. Critical Care Medicine. https://doi.org/10.1097/ccm.0000000000002769
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.